ArticleCancer cell2025
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.Cancer immunology, immunotherapy : CII · 2025Trial
- Loss of short-form Ron promotes B and T cell cooperation to prevent outgrowth of breast cancer bone metastasis.bioRxiv : the preprint server for biology · 2026Article
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Contextualizing TNature reviews. Immunology · 2026Review
- Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Fusion oncoproteins orchestrate tumorigenesis and sustain malignant progression via a positive feedback mechanism.Cell & bioscience · 2026Review
- Reimagining AHR in Cancer: From Environmental Sensor to Novel Immunomodulatory Therapeutic Target.International journal of biological sciences · 2026Review
- B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study.Frontiers in immunology · 2026Article
- Th17-like cells and immunosuppressive macrophages infiltrate tertiary lymphoid structures with distinct maturation status in soft-tissue sarcoma.Cell death & disease · 2025Article
- Constructing the cure: engineering the next wave of antibody and cellular immune therapies.Journal for immunotherapy of cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Anna C ColeDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA. Electronic address: anna.cole@emory.edu.
Hannah M KnochelmannDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
Megan M WyattDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Megen C WittlingDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Natalie K HorvatDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Aubrey S SmithDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
Guillermo O Rangel RiveraDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
Amalia M Rivera ReyesDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Bhavana PavuluriDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Soundharya KumaresanDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Pawel MuranskiColumbia Center for Translational Immunology, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Ayana T RuffinDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Jeremy M BossDepartment of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Gregory B LesinskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Chrystal M PaulosDepartment of Surgery, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA. Electronic address: cpaulos@emory.edu.
Funding
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5MT-COHR: Training in Craniofacial and Oral Health ResearchT32DE017551 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI YAO, HAI · 2006 to 2025
$10.3MMechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cellsR01CA275199 · NCI · EMORY UNIVERSITY · PI Chrystal M Paulos · 2023 to 2026
$2.5MLeveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerR01CA287866 · NCI · EMORY UNIVERSITY · PI Gregory B. Lesinski, Chrystal M Paulos · 2024 to 2026
$1.9MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MTargeting immune stroma interactions in pancreatic cancerR01CA228406 · NCI · EMORY UNIVERSITY · PI EL-RAYES, BASSEL, LESINSKI, GREGORY B. · 2019 to 2023
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MNeoadjuvant SEMA4D/ICB therapy for melanomaR01CA300792 · NCI · EMORY UNIVERSITY · PI Gregory B. Lesinski, Chrystal M Paulos · 2025 to 2026
$1.4MGraduate Program in Cancer Biology Training at Emory UniversityT32CA272392 · NCI · EMORY UNIVERSITY · PI Sumin Kang, Gregory B. Lesinski · 2023 to 2026
$835kResearch Specialist Support of a Well-Established Cancer Immunotherapy Research Program Focused on Improving Adoptive T Cell Therapy (ACT)R50CA233168 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WYATT, MEGAN M · 2018 to 2022
$532kDefining the Role of CD26 in Checkpoint Blockaded Induced Tumor ImmunityR21DE029592 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NESKEY, DAVID M., PAULOS, CHRYSTAL MARY · 2020 to 2021
$411kModulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockadeR21CA266088 · NCI · EMORY UNIVERSITY · PI EL-RAYES, BASSEL, LESINSKI, GREGORY B. · 2022 to 2023
$399kNCI NIH HHS F30 CA243307NCI NIH HHS F30 CA291027NCI NIH HHS F31 CA281258NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA208514NCI NIH HHS R01 CA228406NCI NIH HHS R01 CA275199NCI NIH HHS R01 CA287866NCI NIH HHS R01 CA300792NCI NIH HHS R21 CA266088NCI NIH HHS R21 CA270903NCI NIH HHS R50 CA233168NCI NIH HHS T32 CA272392NIDCR NIH HHS R21 DE029592NIDCR NIH HHS T32 DE017551
Abstract
CD4
Indexed as
Adoptive TransferB-LymphocytesImmunotherapy, AdoptiveMelanoma, ExperimentalTh17 CellsAnimalsCell DifferentiationCell Line, TumorGerminal CenterHumansInterleukin-21InterleukinsLymphocyte ActivationMiceMice, Inbred C57BLInterleukin-21Interleukinsadoptive cell therapyantibodiesB cellscancer immunotherapyCD40germinal centershumoral immunityIL-21melanomaTh17 cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.